Acute Respiratory Distress Syndrome - Pipeline Review, H2 2011

Global Markets Direct, October 2011, Pages: 60

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2011', provides an overview of the Acute Respiratory Distress Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome. 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Respiratory Distress Syndrome.
- A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Acute Respiratory Distress Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Respiratory Distress Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome Therapeutics under Development by Companies
Acute Respiratory Distress Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acute Respiratory Distress Syndrome Therapeutics - Products under Development by Companies
Acute Respiratory Distress Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acute Respiratory Distress Syndrome Therapeutics Development
United Therapeutics Corporation
GlaxoSmithKline plc
Pacgen Biopharmaceuticals Corporation
MediPost Co., Ltd.
Altor BioScience Corporation
NovImmune SA
Ikaria Inc.
Kemin Industries, Inc.
Faron Pharmaceuticals, Ltd.
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Aviptadil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NI-0101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB681323 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAC-G31P - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALT-836 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumostem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APN01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KPE00001175 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Calfactant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TXA127 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IK-3001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human albumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hetastarch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FP-1201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5% Human Albumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Insulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Respiratory Distress Syndrome Therapeutics – Drug Profile Updates
Acute Respiratory Distress Syndrome Therapeutics - Discontinued Products
Acute Respiratory Distress Syndrome - Featured News
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries
Jul 19, 2011: P2D Bioscience Receives NIH Funding To Develop Drugs For Lung Disease
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI
Apr 12, 2011: Faron Completes Recruitment For Phase I/II Clinical Trial Of FP-1201
Nov 18, 2010: Advanced Life Sciences Applies For FDA Orphan Drug Designation For ALS-886 To Treat Acute Lung Injury
Sep 16, 2010: Faron's Lead Product FP-1201 Enters Next Phase Of Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Acute Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Acute Respiratory Distress Syndrome - Pipeline Review, H1 2013
• Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Acute Respiratory Distress Syndrome - Pipeline Review, H1 2012
• Respiratory Distress Syndrome - Pipeline Review, H1 2012
• Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Acute Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012
• Neonatal Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Respiratory Distress Syndrome - Pipeline Review, Q3 2011
• Acute Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011